Management of Advanced Liver Disease and Other Challenging HCV Cases

Led by Paul Y. Kwo, MD, a panel of experts discusses their personal approach to the management of challenging HCV patients.
Mark S. Sulkowski, MD
Program Director
Ira M. Jacobson, MD
Paul Y. Kwo, MD
Thomas Schiano, MD
Released: June 27, 2016 Expiration: No longer available for credit

Related Content

Review key slides on the interplay of COVID-19 and viral hepatitis and review expert strategies for managing chronic liver disease in the COVID-19 era

Released: January 10, 2022

Clinical Care Options (CCO) and Dr. Robert Gish: Interplay of COVID-19 and viral hepatitis, expert strategies for chronic liver disease in the COVID era

Robert G. Gish, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: January 10, 2022 Expired: January 9, 2023

Expert commentary by Dr Mark S. Sulkowski on the importance of investigating elevated liver enzymes in patients with HIV, from Clinical Care Options (CCO)

Mark S. Sulkowski, MD Released: January 10, 2022

Limitations of the APASL guidelines and potential role of using HBcrAg for treatment candidacy and HCC screening, from Clinical Care Options (CCO)

Yasuhito Tanaka, MD, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: January 3, 2022 Expired: January 2, 2023
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Bristol-Myers Squibb
Gilead Sciences
Janssen Therapeutics
Merck & Co., Inc.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings